NO20064274L - 8-hydroksy-5-[(-hydroksy-2[[ (1R)-2-(4-metoksyfenyl)-1-metylyletyl] amino][etyl]-2(1H)-quinolinon monohydroklond i krystallinsk form og fremgangsmaten for dens fremstilling - Google Patents

8-hydroksy-5-[(-hydroksy-2[[ (1R)-2-(4-metoksyfenyl)-1-metylyletyl] amino][etyl]-2(1H)-quinolinon monohydroklond i krystallinsk form og fremgangsmaten for dens fremstilling

Info

Publication number: NO20064274L
Authority: NO; Norway
Prior art keywords: hydroxy; methoxyphenyl; ethyl; amino; crystalline form
Prior art date: 2004-03-24

Application number

NO20064274A

Other languages

English (en)

Norwegian (no)

Inventor

Roberto Pighi

Fausto Pivetti

Original Assignee

Chiesi Farma Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-24

Filing date

2006-09-21

Publication date

2006-10-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34963779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20064274(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-09-21 Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa

2006-10-13 Publication of NO20064274L publication Critical patent/NO20064274L/no

Links

125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 title abstract 2
238000000034 method Methods 0.000 title abstract 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 title abstract 2
GLGOVIORUDCBHW-UHFFFAOYSA-N 1-ethylquinolin-2-one hydrochloride Chemical compound Cl.C(C)N1C(C=CC2=CC=CC=C12)=O GLGOVIORUDCBHW-UHFFFAOYSA-N 0.000 title 1
239000000969 carrier Substances 0.000 abstract 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Quinoline Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO20064274A 2004-03-24 2006-09-21 8-hydroksy-5-[(-hydroksy-2[[ (1R)-2-(4-metoksyfenyl)-1-metylyletyl] amino][etyl]-2(1H)-quinolinon monohydroklond i krystallinsk form og fremgangsmaten for dens fremstilling NO20064274L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP04007045		2004-03-24
PCT/EP2005/003144 WO2005089760A1 (fr)	2004-03-24	2005-03-24	Monohydrochlorure de 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)-quinolinone sous forme cristalline et procede de preparation associe

Publications (1)

Publication Number	Publication Date
NO20064274L true NO20064274L (no)	2006-10-13

Family

ID=34963779

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20064274A NO20064274L (no)	2004-03-24	2006-09-21	8-hydroksy-5-[(-hydroksy-2[[ (1R)-2-(4-metoksyfenyl)-1-metylyletyl] amino][etyl]-2(1H)-quinolinon monohydroklond i krystallinsk form og fremgangsmaten for dens fremstilling

Country Status (30)

Country	Link
US (1)	US20070197586A1 (fr)
EP (1)	EP1729773B1 (fr)
JP (1)	JP2007530489A (fr)
KR (1)	KR20070001946A (fr)
CN (2)	CN1929840B (fr)
AR (1)	AR048339A1 (fr)
AT (1)	ATE399552T1 (fr)
AU (1)	AU2005224032A1 (fr)
BR (1)	BRPI0508213A (fr)
CA (1)	CA2560650A1 (fr)
CY (1)	CY1108323T1 (fr)
DE (1)	DE602005007871D1 (fr)
DK (1)	DK1729773T3 (fr)
EA (1)	EA010128B1 (fr)
ES (1)	ES2309739T3 (fr)
HR (1)	HRP20080495T3 (fr)
IL (1)	IL178227A0 (fr)
MA (1)	MA28549B1 (fr)
MX (1)	MXPA06010515A (fr)
NO (1)	NO20064274L (fr)
NZ (1)	NZ550010A (fr)
PE (1)	PE20060159A1 (fr)
PL (1)	PL1729773T3 (fr)
PT (1)	PT1729773E (fr)
RS (1)	RS50602B (fr)
SI (1)	SI1729773T1 (fr)
TN (1)	TNSN06249A1 (fr)
UA (1)	UA86221C2 (fr)
WO (1)	WO2005089760A1 (fr)
ZA (1)	ZA200607907B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1953143A1 (fr) *	2007-01-30	2008-08-06	CHIESI FARMACEUTICI S.p.A.	Processus de préparation de monohydrochloride de 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-méthoxyphényl)-1-méthyléthyl]amino]éthyl]-2(1H)-quinolinone
EP2116537A1 (fr) *	2008-05-07	2009-11-11	CHIESI FARMACEUTICI S.p.A.	Polymorphe de monohydrochloride de 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-méthoxyphényl)-1-méthyléthyl]amino]éthyl]-2(1H)-quinolinone
EP2116536A1 (fr)	2008-05-07	2009-11-11	CHIESI FARMACEUTICI S.p.A.	Forme cristalline de monohydrochloride de 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-méthoxyphényl)-1-méthyléthyl]amino]éthyl]-2(1H)-quinolinone
WO2011015289A1 (fr)	2009-08-04	2011-02-10	Chiesi Farmaceutici S.P.A.	Hémi-fumarate de 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2- (4-méthoxyphényl)-1-méthyléthyl]amino]éthyl]-2(1h)-quinolinone
EP2360147A1 (fr)	2010-02-22	2011-08-24	CHIESI FARMACEUTICI S.p.A.	Procédé de préparation de particules crystallines d'un sel de 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8334494D0 (en) *	1983-12-24	1984-02-01	Tanabe Seiyaku Co	Carbostyril derivatives
GB9603237D0 (en) *	1996-02-16	1996-04-17	Sandoz Ltd	Organic compounds
SE9700135D0 (sv) *	1997-01-20	1997-01-20	Astra Ab	New formulation
EP1654001A2 (fr) *	2003-08-05	2006-05-10	Boehringer Ingelheim International GmbH	Medicament pour inhalation comprenant des steroides et un betamimetique
EP1953143A1 (fr) *	2007-01-30	2008-08-06	CHIESI FARMACEUTICI S.p.A.	Processus de préparation de monohydrochloride de 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-méthoxyphényl)-1-méthyléthyl]amino]éthyl]-2(1H)-quinolinone
EP2116537A1 (fr) *	2008-05-07	2009-11-11	CHIESI FARMACEUTICI S.p.A.	Polymorphe de monohydrochloride de 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-méthoxyphényl)-1-méthyléthyl]amino]éthyl]-2(1H)-quinolinone
EP2116536A1 (fr) *	2008-05-07	2009-11-11	CHIESI FARMACEUTICI S.p.A.	Forme cristalline de monohydrochloride de 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-méthoxyphényl)-1-méthyléthyl]amino]éthyl]-2(1H)-quinolinone

2005
- 2005-03-23 AR ARP050101185A patent/AR048339A1/es not_active Application Discontinuation
- 2005-03-23 PE PE2005000338A patent/PE20060159A1/es not_active Application Discontinuation
- 2005-03-24 CN CN2005800076387A patent/CN1929840B/zh not_active Expired - Fee Related
- 2005-03-24 EA EA200601531A patent/EA010128B1/ru not_active IP Right Cessation
- 2005-03-24 WO PCT/EP2005/003144 patent/WO2005089760A1/fr not_active Ceased
- 2005-03-24 RS RSP-2008/0393A patent/RS50602B/sr unknown
- 2005-03-24 HR HR20080495T patent/HRP20080495T3/xx unknown
- 2005-03-24 AT AT05730069T patent/ATE399552T1/de not_active IP Right Cessation
- 2005-03-24 CN CN200910173473A patent/CN101812017A/zh active Pending
- 2005-03-24 DK DK05730069T patent/DK1729773T3/da active
- 2005-03-24 EP EP05730069A patent/EP1729773B1/fr not_active Expired - Lifetime
- 2005-03-24 SI SI200530320T patent/SI1729773T1/sl unknown
- 2005-03-24 AU AU2005224032A patent/AU2005224032A1/en not_active Abandoned
- 2005-03-24 MX MXPA06010515A patent/MXPA06010515A/es active IP Right Grant
- 2005-03-24 JP JP2007504359A patent/JP2007530489A/ja not_active Withdrawn
- 2005-03-24 DE DE602005007871T patent/DE602005007871D1/de not_active Expired - Lifetime
- 2005-03-24 KR KR1020067015966A patent/KR20070001946A/ko not_active Ceased
- 2005-03-24 UA UAA200609448A patent/UA86221C2/uk unknown
- 2005-03-24 US US10/593,571 patent/US20070197586A1/en not_active Abandoned
- 2005-03-24 PL PL05730069T patent/PL1729773T3/pl unknown
- 2005-03-24 CA CA002560650A patent/CA2560650A1/fr not_active Abandoned
- 2005-03-24 ES ES05730069T patent/ES2309739T3/es not_active Expired - Lifetime
- 2005-03-24 NZ NZ550010A patent/NZ550010A/en unknown
- 2005-03-24 PT PT05730069T patent/PT1729773E/pt unknown
- 2005-03-24 BR BRPI0508213-7A patent/BRPI0508213A/pt not_active IP Right Cessation
2006
- 2006-08-04 TN TNP2006000249A patent/TNSN06249A1/en unknown
- 2006-09-21 NO NO20064274A patent/NO20064274L/no not_active Application Discontinuation
- 2006-09-21 IL IL178227A patent/IL178227A0/en not_active IP Right Cessation
- 2006-09-21 ZA ZA2006/07907A patent/ZA200607907B/en unknown
- 2006-10-23 MA MA29409A patent/MA28549B1/fr unknown
2008
- 2008-09-04 CY CY20081100962T patent/CY1108323T1/el unknown

Also Published As

Publication number	Publication date
ES2309739T3 (es)	2008-12-16
ATE399552T1 (de)	2008-07-15
BRPI0508213A (pt)	2007-07-17
EA010128B1 (ru)	2008-06-30
EP1729773B1 (fr)	2008-07-02
UA86221C2 (en)	2009-04-10
MA28549B1 (fr)	2007-04-03
WO2005089760A1 (fr)	2005-09-29
DE602005007871D1 (de)	2008-08-14
PE20060159A1 (es)	2006-04-04
AU2005224032A1 (en)	2005-09-29
MXPA06010515A (es)	2007-03-30
EP1729773A1 (fr)	2006-12-13
CN1929840A (zh)	2007-03-14
CA2560650A1 (fr)	2005-09-29
EA200601531A1 (ru)	2007-04-27
CN101812017A (zh)	2010-08-25
JP2007530489A (ja)	2007-11-01
RS50602B (sr)	2010-05-07
HRP20080495T3 (hr)	2008-11-30
NZ550010A (en)	2010-08-27
ZA200607907B (en)	2008-04-30
SI1729773T1 (sl)	2008-10-31
AR048339A1 (es)	2006-04-19
IL178227A0 (en)	2006-12-31
PL1729773T3 (pl)	2008-12-31
CY1108323T1 (el)	2014-02-12
DK1729773T3 (da)	2008-10-20
KR20070001946A (ko)	2007-01-04
TNSN06249A1 (en)	2007-12-03
CN1929840B (zh)	2010-12-08
PT1729773E (pt)	2008-09-29
US20070197586A1 (en)	2007-08-23

Legal Events

Date	Code	Title	Description
2011-10-24	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
US8633219B2 (en)	2014-01-21	Combination therapy
FI4159217T3 (fi)	2024-08-15	Mek-estäjän ja b-raf-estäjän käsittävä yhdistelmä
WO2012047017A3 (fr)	2012-05-31	Dérivé 2,3-dihydro-isoindol-1-one et composition le comprenant
WO2009049180A3 (fr)	2009-05-28	Amides d'hétéroaryle utilisés comme inhibiteurs de canaux sodiques sensibles à une différence de potentiel
TNSN05186A1 (en)	2007-06-11	Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients
TW200626601A (en)	2006-08-01	Novel compounds
WO2006011050A3 (fr)	2006-10-05	Derives de pyridine
WO2007120647A3 (fr)	2007-11-29	Compositions utiles en tant qu'inhibiteurs de canaux sodiques sensibles a la tension
IL176416A (en)	2013-05-30	History of Nitroxy prostaglandin, pharmaceutical preparations containing them, and their use in the preparation of the drug for the treatment of glaucoma or intraocular pressure
JP2008504266A5 (fr)	2008-08-07
WO2002102793A3 (fr)	2003-04-10	Agents antibacteriens
WO2004094386A8 (fr)	2005-02-17	Utilisation d'amides d'acide isoquinoline-5-sulfonique comme inhibiteurs de l'akt (proteine kinase b)
WO2009066041A3 (fr)	2009-12-17	Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2006077025A3 (fr)	2006-09-08	Morpholines en tant qu'agonistes de 5ht2c
PL1753723T3 (pl)	2009-01-30	Podstawione pochodne chinoliny jako inhibitory kinezyn mitotycznych
WO2005075450A3 (fr)	2006-03-30	Nouveaux composes spiro-pentacycliques
NO20064274L (no)	2006-10-13	8-hydroksy-5-[(-hydroksy-2[[ (1R)-2-(4-metoksyfenyl)-1-metylyletyl] amino][etyl]-2(1H)-quinolinon monohydroklond i krystallinsk form og fremgangsmaten for dens fremstilling
JP2003522768A5 (fr)	2011-09-08
MX2009007868A (es)	2009-07-31	Proceso para la preparacion de monoclorhidrato de 8-hidroxi-5-[(1r)-1-hidroxi-2[[(1r)-2-(4-metoxifenil)-1-metiletil ]amino]-etil]-2(1h)-quinolinona.
WO2005090287A3 (fr)	2006-02-16	Composes convenant pour le traitement de maladies
WO2008021725A3 (fr)	2008-10-16	Composés chimiques
ZA200609337B (en)	2008-08-27	Use of opioid antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin
WO2006052886A8 (fr)	2007-06-14	Metabolites de certains derives de [1,4]diazepino[6,7,1-ij] quinoline et procedes de preparation et d'utilisation de ceux-ci
WO2008068272A3 (fr)	2008-07-24	Dérivés de quinoline antibactériens
WO2007014934A3 (fr)	2007-04-05	Derives de quinoleine utilises comme agents antibacteriens